Medical Condition News

RSS

Epilepsy not getting the public attention and research funding it deserves

Epilepsy, a common and serious neurologic disorder that affects millions of people, is not getting the public attention and funding for research it deserves, according to an editorial on a study published in the January 4, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology.

28 Dec 2010

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.

28 Dec 2010

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

Three weeks of oral resveratrol or Longevinex- ingestion prior to an induced heart attack returned microRNA activity close to their pre-event levels in excised animal hearts. Among thousands of microRNA's studied, just six were attributed to exerting the majority of the gene-switching effects measured in the animal heart study - four microRNA optimally regulated by Longevinex- and two optimally by plain resveratrol.

28 Dec 2010

U.S judge awards $11.7 million to DF/HCC for large-scale prostrate cancer research

Dana Farber/Harvard Cancer Center will launch a new multi-million dollar grant award program focused on prostate cancer research. It will be administered in collaboration with the Prostate Cancer Foundation.

28 Dec 2010

Cephalon receives second FDA Complete Response Letter for NUVIGIL sNDA

Cephalon, Inc. today announced that the company received a second Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the supplemental new drug application (sNDA) for NUVIGIL(R) (armodafinil) Tablets [C-IV] for the treatment of patients with excessive sleepiness associated with jet lag disorder resulting from eastbound travel. In its letter to the company, the FDA reiterated its previously stated concerns regarding the NUVIGIL sNDA.

28 Dec 2010

King Pharmaceuticals resubmits NDA for REMOXY

King Pharmaceuticals®, Inc. and Pain Therapeutics®, Inc. today announced that King has resubmitted a New Drug Application for REMOXY® to the U.S. Food and Drug Administration in response to a Complete Response letter received by Pain Therapeutics in December 2008.

28 Dec 2010

Biglycan protein offers potential therapy for muscular dystrophy

A novel potential therapy based on a natural human protein significantly slows muscle damage and improves function in mice who have the same genetic mutation as boys with the most common form of muscular dystrophy, according to a paper published online Dec. 27 in the Proceedings of the National Academy of Sciences.

28 Dec 2010

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia.

28 Dec 2010

NDA resubmitted for DURECT's ORADUR technology based REMOXY

DURECT Corporation today reported that King Pharmaceuticals, Inc. and Pain Therapeutics, Inc. have announced that King has resubmitted a New Drug Application (NDA) for REMOXY® to the U.S. Food and Drug Administration (FDA) in response to a Complete Response Letter received by Pain Therapeutics in December 2008. This is a Class 2 resubmission with a six month review cycle.

28 Dec 2010

Researchers receive $6.78 million NIH grant for community-based study on heart disease

Researchers at the Methodist DeBakey Heart & Vascular Center in Houston were recently awarded a $6.78 million grant from the National Institutes of Health to extend a 23-year-old large-scale, community-based study of heart disease.

27 Dec 2010

Vitamin D levels of newborns appear to predict their risk of respiratory infections

The vitamin D levels of newborn babies appear to predict their risk of respiratory infections during infancy and the occurrence of wheezing during early childhood, but not the risk of developing asthma. Results of a study in the January 2011 issue of Pediatrics support the theory that widespread vitamin D deficiency contributes to risk of infections.

27 Dec 2010

Stem cell therapy helps patient with diabetes gangrene recover from foot ulcer: ICMS conference

During ICMS Annual International Congress on Regenerative and Cell Based Medicine Conference held on November 12, 2010 in Las Vegas, Nevada, it was announced that a patient with complications of diabetes gangrene recovered from foot ulcer through stem cell therapy.

27 Dec 2010

Great River Medical Center's Board of Directors approve construction of new long-term-care center

Great River Medical Center's Board of Directors has approved construction of a new long-term-care center on the hospital's West Burlington, Iowa campus. It will replace the existing Klein Center at 2910 Madison Ave., Burlington, Iowa.

27 Dec 2010

Near-complete data sets from fruit fly and roundworm genomes

An Ontario researcher has played a key role in the development of a new resource that will help genomics researchers around the world find new ways to prevent and treat cancer.

24 Dec 2010

New study shows striking changes, variations by region in admission rates for substance abuse treatment

Although the overall rate of admissions to substance abuse treatment in the U.S. remained stable between 1998 and 2008, at about 770 admissions for every 100,000 persons in the population, a new study shows striking changes and variations in admission rates by region. For example, the rate of admissions for alcohol as the primary drug has declined by 15 percent nationally. However admission rates for alcohol in West North Central states (Ark., Iowa, Kan., Minn., Mo., N.D., Neb. and S.D.) remained the same.

24 Dec 2010

Gold-coated liposomes could make chemotherapy more effective without harmful side effects

University of Arizona researchers may have found a way to deliver chemotherapeutic drugs to cancer tissues in controlled doses without harming healthy body cells.

24 Dec 2010

New derivation of stem cells from fat cells hold promise for therapeutic, cosmetic benefits

Two studies appearing in the current issue of Cell Transplantation 19(10) discuss stem cells derived from adipose (fat) cells and their potential use in plastic surgery and tissue reconstruction. The studies are now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ .

24 Dec 2010

AMPK activates autophagy by activating ATG1 enzyme

Researchers at the Salk Institute for Biological Studies have discovered how AMPK, a metabolic master switch that springs into gear when cells run low on energy, revs up a cellular recycling program to free up essential molecular building blocks in times of need.

24 Dec 2010

60% of type 2 diabetics who use insulin would switch to a less expensive biosimilar insulin if available

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 60 percent of surveyed type 2 diabetes patients in the U.S. who currently use insulin indicate they would request that their doctor switch them to a less expensive biosimilar insulin if such an agent became available.

24 Dec 2010

Good Clostridia prevents development of allergies and inflammatory bowel disease

Scientists at the University of Tokyo have discovered that specific gut-dwelling bacteria control key immune cells that combat allergies and autoimmune diseases. The paper describing these findings was published in today's issue of the journal Science, and technology originating from the work is being advanced by start-up Vedanta Biosciences.

24 Dec 2010

Medical Condition News

Epilepsy not getting the public attention and research funding it deserves

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

U.S judge awards $11.7 million to DF/HCC for large-scale prostrate cancer research

Cephalon receives second FDA Complete Response Letter for NUVIGIL sNDA

King Pharmaceuticals resubmits NDA for REMOXY

Biglycan protein offers potential therapy for muscular dystrophy

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

NDA resubmitted for DURECT's ORADUR technology based REMOXY

Researchers receive $6.78 million NIH grant for community-based study on heart disease

Vitamin D levels of newborns appear to predict their risk of respiratory infections

Stem cell therapy helps patient with diabetes gangrene recover from foot ulcer: ICMS conference

Great River Medical Center's Board of Directors approve construction of new long-term-care center

Near-complete data sets from fruit fly and roundworm genomes

New study shows striking changes, variations by region in admission rates for substance abuse treatment

Gold-coated liposomes could make chemotherapy more effective without harmful side effects

New derivation of stem cells from fat cells hold promise for therapeutic, cosmetic benefits

AMPK activates autophagy by activating ATG1 enzyme

60% of type 2 diabetics who use insulin would switch to a less expensive biosimilar insulin if available

Good Clostridia prevents development of allergies and inflammatory bowel disease

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Latest News